The effect of hypothyroidism and thyroxine replacement on hepatic and intestinal HMG-CoA reductase and ACAT activities and biliary lipids in the rat.
Hepatic and intestinal cholesterol metabolism were investigated in the hypothyroid and thyroxine-treated hypothyroid rat. Plasma cholesterol levels were significantly increased in hypothyroid animals. After thyroxine administration, plasma cholesterol levels were reduced to levels observed in euthyroid controls. Hypothyroidism caused a significant decrease in biliary cholesterol output, which was reversed with thyroxine treatment. In contrast, biliary bile acid output was unchanged by the thyroid status. Cholesterol synthesis, as estimated by HMG-CoA reductase activity, was decreased in the liver of hypothyroid animals. Thyroxine administration, however, significantly increased reductase activity returning it to control levels. Hypothyroidism did not affect HMG-CoA reductase activity in the intestine, but thyroxine administration markedly stimulated the activity of this enzyme in this organ. Cholesterol esterification, as estimated by ACAT activity, was decreased in the liver of hypothyroid rats, while intestinal ACAT activity was greatly increased. Thyroxine treatment reversed these effects of hypothyroidism on ACAT activity in both organs. An increase in microsomal cholesterol content in the intestine of hypothyroid rats was associated with the observed increase in intestinal ACAT activity. The percent of cholesterol that was absorbed in the intestine was not changed by the thyroid status of the animal. The data suggest that the changes observed in cholesterol metabolism in hypothyroid rats or hypothyroid rats treated with thyroxine for 1 week cannot account for the increase in plasma cholesterol levels observed in the hypothyroid rat. This implies that other factors that were not studied, such as changes in lipoprotein catabolism, are likely to contribute to the hypercholesterolemia of hypothyroidism.
D000818:Animals; D001646:Bile / Q000378:metabolism*; D002784:Cholesterol / Q000032:analysis; D006903:Hydroxymethylglutaryl CoA Reductases / Q000378:metabolism*; D007037:Hypothyroidism / Q000188:drug therapy / Q000201:enzymology*; D007408:Intestinal Absorption; D007422:Intestines / Q000201:enzymology*; D050356:Lipid Metabolism; D008099:Liver / Q000201:enzymology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D002785:Sterol O-Acyltransferase / Q000378:metabolism*; D013974:Thyroxine / Q000627:therapeutic use*
D002784:Cholesterol; D006903:Hydroxymethylglutaryl CoA Reductases; D002785:Sterol O-Acyltransferase; D013974:Thyroxine